OxyContin
(Oxycodone)ApprovedSmall molecule
Oxycodone is a strong painkiller used to treat moderate to severe pain, such as pain from cancer, surgery, or serious injuries. It works by changing how the brain responds to pain signals.[2] OxyContin is currently approved and in use across 65 indications[4].[1]
OxyContin is one of 909 small molecule programs targeting Total Knee Arthroplasty. It is currently in Approved.
65
Indications
246
Total Trials
20
Active Trials
908
Competitors
9
FDA Applications
NDA/BLA/ANDA regulatory filings
19
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 62 indications
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1OxyContin
PProtega
Approved
Rubraca
Bristol-Myers SquibbPhase 3
Verzenio
Eli LillyPhase 3
Acetylsalicylic Acid
BayerPhase 3
Antiandrogen Therapy
UUniversity of Washington
Phase 3
Lhrha
Johnson & JohnsonPhase 3
Gnrh Agonist/antagonist
NNorthwestern University
Phase 3
Lupron Depot
RRepros Therapeutics Inc.
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Oxycodone14 trials
Show 11 more trials
Cancer Pain9 trials
Show 6 more trials
Post Operative Pain8 trials
Show 5 more trials
Abuse Potential7 trials
Show 4 more trials
Hysterectomy6 trials
105 more indications
Pain Control5 trials
Pain Management5 trials
Opioids4 trials
Reducing the Abuse Liability of Prescription Opioids
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT04587115·15 enrolled
Show 1 more trial
Total Knee Arthroplasty4 trials
Osteoarthritis4 trials
Low back pain4 trials
Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms
Completed·—·Phase 4·NCT01502644·81 enrolled
Analgesic3 trials
Interaction3 trials
Postoperative Pain Control3 trials
Buprenorphine3 trials
Opioid3 trials
Visceral Pain2 trials
Effectiveness2 trials
Fed2 trials
ACL Reconstruction2 trials
Tonsillectomy2 trials
Non-opioids for Analgesia After Adenotonsillectomy in Children
Terminated·—·Phase 1/2·NCT03618823·268 enrolled
Celecoxib After Tonsillectomy
Completed·—·Phase 2·NCT02934191·172 enrolled
Tics2 trials
Cesarean Delivery2 trials
Pregabalin2 trials
Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia
Unknown status·—·Phase 2/3·NCT05389813·150 enrolled
Safety and Efficacy2 trials
Impairment2 trials
Chronic pain2 trials
Dexmedetomidine2 trials
Intravenous2 trials
Multimodal Analgesia2 trials
Multimodal Analgesia Strategies After Major Shoulder Ambulatory Surgery
Completed·—·Phase 4·NCT04110665·92 enrolled
Analgesic Efficacy2 trials
Pediatric2 trials
After Cardiac Surgery2 trials
Pain Management After Cardiac Surgery - Opioids or NSAID
Completed·—·Phase 4·NCT02479165·182 enrolled
Constipation2 trials
Ankle Surgery1 trial
Inflammatory Response1 trial
The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE
Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT06041425·40 enrolled
Postoperative Analgesia1 trial
Gastrointestinal1 trial
Postoperative Pain Management1 trial
Personalized Post-Operative Pain Management
Active, not recruiting·UUniversity of Tennessee Graduate School of Medicine·Phase 4·NCT06669650·208 enrolled
Clinical Trial1 trial
Craniotomy1 trial
Surgical1 trial
Obesity1 trial
Sedation1 trial
Adolescent1 trial
Hip Fracture1 trial
Epidural Analgesia1 trial
Bronchoscopy1 trial
Emergency Department Patient1 trial
Perioperative Analgesia1 trial
Laceration1 trial
The Addition of Oral Analgesics to LET During Laceration Repair
Suspended·—·N/A·NCT01268670·150 enrolled
Patient Satisfaction1 trial
Total Joint Arthroplasty1 trial
Experimental1 trial
Radius Fracture1 trial
Withdrawal1 trial
Colorectal Surgery1 trial
Mucositis1 trial
Early Use of Opioid in Radiation Mucositis
Completed·—·Phase 2·NCT02309437·200 enrolled
Arterial Occlusive Disease1 trial
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
Unknown status·AAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia·N/A·NCT02455726·150 enrolled
Knee Replacement Surgery1 trial
Postoperative Pain Relief1 trial
Liposomal Bupivacaine1 trial
Opioid Use1 trial
Postherpetic Neuralgia1 trial
Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT03120962·140 enrolled
Total Hip Arthroplasty1 trial
Analgesia1 trial
Sleep Apnea1 trial
Impact of Tramadol and Oxycodone on Sleep Apnea
Completed·—·Phase 4·NCT03454217·60 enrolled
Chronic Kidney Disease1 trial
Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis
Unknown status·EEmerio & Lourdes Linares Research and Education Center·Phase 4·NCT02452437·20 enrolled
Third Molar1 trial
Nausea1 trial
Multimodal Pain Management1 trial
Inguinal hernia1 trial
Prostate Cancer1 trial
Efficacy and Safety1 trial
Single Dose1 trial
Peripheral Neuropathy1 trial
Central Nervous System1 trial
Chronic Rhinosinusitis1 trial
Heart Disease1 trial
Perioperative Pain1 trial
Oral Mucositis1 trial
Unspecified3 trials
Tapentadol (CG5503)
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00421928·1,030 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00421928·1,030 enrolledRegulatory
FDA Approval Timeline[5]
Oct 26, 1998
ROXICODONE
NDA NDA020932
May 15, 2009
ROXICODONE
NDA NDA021011
Apr 5, 2010
OXYCONTIN
NDA NDA022272
Oct 20, 2010
OXYCODONE HYDROCHLORIDE
NDA NDA200534
Jun 17, 2011
OXAYDO
NDA NDA202080
Jan 12, 2012
OXYCODONE HYDROCHLORIDE
NDA NDA201194
Aug 22, 2013
OXYCODONE HYDROCHLORIDE
NDA NDA200535
Apr 26, 2016
XTAMPZA ER
NDA NDA208090
Apr 20, 2017
ROXYBOND
NDA NDA209777
Sources
References
- [1]
- [2]MedlinePlus Drug Information — OxyContin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Oxycodone. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]